Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
10 Outubro 2023 - 5:05PM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-class1 therapeutics that
combine both targeted and immune-mediated mechanisms, today
announced the company plans to report new and updated data from the
global randomized Phase 1b/2 combination study of TPST-1120 with
atezolizumab and bevacizumab in first-line treatment of
hepatocellular carcinoma (HCC) in a premarket press release on
Wednesday, October 11, 2023, followed by a webcasted conference
call with associated slide presentation at 8:30 a.m. ET on
Wednesday, October 11, 2023.
To join the conference call via phone and
participate in the live Q&A session, please pre-register online
here to receive a telephone number and unique passcode required to
enter the call. The live webcast and audio archive of the
presentation may be accessed on the investor section of the Tempest
website at https://ir.tempesttx.com/. The webcast will be
available for replay for 30 days.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company has a diverse portfolio
of novel programs ranging from early research to investigation in a
randomized global study in first-line cancer patients. The
company’s two novel clinical programs, TPST-1120 and TPST-1495,
target PPARα and EP2/EP4, respectively, and are advancing through
trials designed to study the agents as monotherapies and in
combination with approved agents. Tempest is also developing an
orally available inhibitor of TREX1, a target that controls
activation of the cGAS/STING pathway. Tempest is headquartered in
Brisbane, California. More information about Tempest can be found
on the company’s website at www.tempesttx.com. Investor
Contacts:
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
1 If approved by the FDA
Tempest Therpeutics (NASDAQ:TPST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Tempest Therpeutics (NASDAQ:TPST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024